Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative toripalimab plus neoadjuvant chemotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma
CTR20210766Phase 3Active
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Jun 2021; status: active.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20210766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210766.